Professional paper

https://doi.org/10.15836/ccar.2015.250

Krka's cardiovascular medicines − value-added generic medicines

Breda Barbič-Žagar orcid.org/0000-0002-1173-7361 ; Krka, d. d., Novo mesto, Slovenia
Mateja Grošelj ; Krka, d. d., Novo mesto, Slovenia

Abstract

In the past six decades, Krka has emerged as one of the leading generic pharmaceutical companies in the world. Our innovative generics, i.e. value-added generic medicines, are developed using the company’s own know-how. This ensures that our products hold certain key advantages over competitor products, resulting from the development of new technologies used in the production of active ingredients and dosage forms. Our key therapeutic area in prescription pharmaceuticals is cardiovascular medicines. We offer a wide range of cardiovascular medicines, available in a variety of different dosage forms, fixed-dose combinations and innovative strengths, which enable doctors to optimize the treatment of their patients. The therapeutic equivalence of Krka’s product with the originator’s product is demonstrated by in vivo bioequivalence studies. The results of numerous clinical studies have shown that our medicines are clinically proven, effective, and well tolerated by patients in real clinical practice.

Keywords

value-added generics; cardiovascular medicines; dosage-forms; fixed-dose combinations; innovative strengths; clinical studies

Hrčak ID:

146405

URI

https://hrcak.srce.hr/146405

Publication date:

1.10.2015.

Article data in other languages: croatian

Visits: 1.816 *